Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Heart Frequency in Healthy Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy~* Fasting plasma glucose within normal limits (80-100 mg/dl)~* BMI (Body Mass Index): 20.0-29.0 kg/m\^2 (inclusive)~* Heart rate within the range of 50-90 beats per minute (inclusive)~* Subject is judged to be in good health on the basis of their medical history, physical examination, ECG (electrocardiogram), and routine laboratory data~Exclusion Criteria:~* Any clinically significant disease history, in the opinion of the investigator, of systemic or organ disease~* Any clinically significant disease history, in the opinion of the investigator, of cardiovascular disease~* Clinically significant abnormalities on any pre-study clinical examination or any abnormal laboratory measurements during screening~* A family history of sudden cardiac death at age less than 50 years old~* T-wave abnormalities~* Individual or familial history of long QT Syndrome~* Positive results on Screening for Hepatitis B surface antigen, Hepatitis C antibody or HIV (human immunodeficiency virus) antibody~* Positive results on the urine drug and alcohol screen~* Any regular use of prescription or nonprescription drugs or vitamins and herbal/nutritional supplements that cannot be stopped at screening~* Any strenuous exercise (as judged by the investigator) from 4 days prior to randomisation and during the entire trial period~* Blood donation, trauma or surgery with blood loss exceeding 500 ml within the last 2 months prior to dosing~* Subject is a smoker, occasional smoker or has a history of smoking (or use of any tobacco) within the last 3 months~* Excessive use of methylxanthine-containing beverages (more than 8 cups/day of coffee, tea, soda or chocolate)~* Females who are pregnant, breastfeeding, intend to become pregnant within the next 3 months, or who are judged to be using inadequate contraceptive measures~* A history (within the last 2 years) of drug or alcohol abuse

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Double-blind / liraglutide (Type: EXPERIMENTAL): None
- Double-blind / placebo (Type: PLACEBO_COMPARATOR): None
- Open-label / moxifloxacin (Type: ACTIVE_COMPARATOR): None
- Open-label / placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).